FASN and neoplasm: Two PDX cases containing high CSN6 with concurrent high FASN (CRC5647, CRC2849) and two other PDX cases containing low CSN6 with concurrent low FASN (CRC4232, CRC3707) were selected for tumor growth studies under the orlistat treatment (Fig. 7d).